We describe the full-length (72 kDa) myotonin protein kinase (Mt-PK) and demonstrate its kinase activity. The 72-kDa protein corresponds to the translation product from the first in-frame AUG codon. Ser residue and phosphorylates the synthetic peptide Gly-ArgGly-Leu-Ser-Leu-Ser-Arg, which contains a Ser residue in the phosphorylation site. We examined phosphorylation of the voltage-dependent Ca2+ release channel, or dihydropyridine receptor (DHPR), by recombinant Mt-PK. We observed that the f3 subunit of DHPR was phosphorylated in vitro by Mt-PK. A a8-subunit DHPR peptide containing some of the Ser residues predicted to be phosphorylated was synthesized and found to be a substrate for Mt-PK in vitro. We conclude that the 72-kDa Mt-PK has a protein kinase activity specific for Ser residues.
Myotonic dystrophy (DM) is an autosomal dominant multisystem disease that is characterized by muscle weakness, atrophy, and myotonia (1) . The molecular basis of DM is thought to be an amplified trinucleotide (CTG)n repeat located in the 3' untranslated region of the myotonin protein kinase (Mt-PK) gene. The predicted amino acid sequence of Mt-PK shows a high degree of homology to Ser/Thr kinases (2) (3) (4) . A number of polyclonal anti-peptide antibodies to the predicted protein sequence of Mt-PK were developed, all recognizing a 52-to 55-kDa protein in muscle extracts (5) (6) (7) . One antiserum also recognized a major 42-kDa protein in brain (6). We observed a reduced level of 55-kDa protein in the skeletal muscle of adult-onset DM patients (5), associated with trinucleotide amplification. Contradicting results regarding the steady-state levels of Mt-PK mRNA have been reported. We found reduced levels of Mt-PK mRNA (5) , in agreement with data observed by others (8) (9) (10) (11) , whereas Sabourin et aL (12) have described increased expression of the mutant Mt-PK mRNA in DM patients (12) . To our knowledge, no data on protein expression in the DM patients with increased or unchanged steady-state levels of Mt-PK mRNA have been reported. The size of the primary translation product of Mt-PK mRNA has also been unclear. The expected size of the translation product from the longest open reading frame is -72 kDa, but analysis of the Kozak sequence around AUG codons within the Mt-PK mRNA raises the possibility of alternatively initiated translation products. Translation initiating from alternative AUG codons could yield several different Mt-PK isoforms, including a 55-kDa protein. Further- The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. more, multiple splice forms of Mt-PK mRNA have been described (5, 13) , predicting a diversity in the range of protein isoforms. To our knowledge, no data were reported regarding the Mt-PK activity in normal and DM cells. Study of the 54-kDa protein, precipitated from muscle cells extract, revealed Tyr phosphorylation (14) . In another study (15) , recombinant Mt-PK, expressed from constructs containing only putative kinase domain or the kinase and a-helical coiled-coil domain, was reported to have autophosphorylated the recombinant truncated Mt-PK, with specificity for Thr and Ser residues. Our failed attempts to find kinase activity in the 55-kDa protein from normal muscle prompted a search for a Mt-PK with kinase activity.
In this paper, we describe a full-length Mt-PK of 72 kDa and determine the specificity of kinase activity of recombinant Mt-PK with synthetic substrates. In addition, we investigated the phosphorylation of a protein that may be a candidate ligand for Mt-PK in muscle. Since Ca2+ conductance abnormalities may contribute to hyperexcitability of the sarcoplasmic membrane in DM, we initially focused on the voltagegating L-type Ca2+ channel, or dihydropyridine receptor (DHPR), as a potential substrate for Mt-PK. Here we describe the phosphorylation of the ,B subunit of DHPR in vitro by recombinant Mt-PK.
METHODS
Production of Mt-PK Antibodies. Mt-PK amino acid sequence was analyzed to predict hydrophilicity, surface probability, secondary structure, and antigenicity. One peptide (Pro-Gly-Thr-Gly-Ser-Tyr-Gly-Pro-Glu-Cys-Asp-Trp) from the kinase domain was chosen as a potential antigen. This peptide was synthesized and used for antibody production in rabbits by Research Genetics (Huntsville, AL). The immunoglobulin fraction of antisera against Pro-Gly-Thr-Gly-Ser-TyrGly-Pro-Glu-Cys-Asp-Trp (antiserum 8391) was purified on protein A-agarose and used for immunoblot analysis.
Two additional Mt-PK-specific antibodies were used, one (antibody 10033) was raised against a truncated Mt-PK produced with the prokaryotic expression vector pRSET (Invitrogen) and the other (antibody 254) was raised against synthetic Mt-PK peptide (5 7 .0/500 mM NaCl/leupeptin (0.5 ,ug/ml)/pepstatin (20 ,ug/ml). Cells were frozen overnight at -20°C and then lysed by sonication. The lysate was centrifuged at 8000 x g for 20 min at 4°C and fusion proteins were isolated from the supernatant by affinity chromatography with Ni2+ resin (Qiagen, Chatsworth, CA), by the manufacturer's protocol.
Immunoblot Analysis. Human fibroblast cell lines were grown in lx minimum essential medium supplemented with glutamine (0.29 mg/ml) and penicillin/streptomycin (1000 units/ml and 100 ,ug/ml, respectively). Cells were washed twice with PBS. One milliliter of RIPA buffer (50 mM NaCl/1% Nonidet P-40/0.5% sodium deoxycholate/0.1% SDS/50 mM Tris HCl, pH 7.5) was added to a 100-mm dish, which was incubated on ice for 30 min. Cells and debris were scraped and centrifuged for 10 min at 10,000 x g and 4°C.
For assessment of protein phosphorylation, human fibroblasts were grown as above in medium without phosphate but with the addition of [32P]phosphate (0.25 mCi/100-mM dish;
1 Ci = 37 GBq). Cells were grown with radioactivity for 6 h and protein extracts were made with RIPA buffer. For Mt-PK immunoprecipitation, 100 ,A of the protein extract was diluted with 150 mM NaCl/50 mM Tris-HCl, pH 7.6/leupeptin (0.5 ,ug/ml)/pepstatin (20 ,ug/ml) and 15 ,ul of the protein Aagarose and 10 ,ul of antibody 10033 were added. After overnight incubation at 4°C, immunoprecipitate was collected by centrifugation at 4000 x g and washed five times with 1.0 ml of 150 mM NaCl/50 mM Tris HCl/leupeptin (0.5 jig/ml)/ pepstatin (20 ,ug/ml). Labeled Mt-PK was eluted with 20 ,1 of 100 mM glycine (pH 3.0), neutralized with 1.0 M Tris-HCl (pH 8.0), and loaded onto an 8% polyacrylamide gel.
Nuclear extracts and cytoplasm were prepared with a rapid procedure. Fibroblasts were scraped, washed with PBS, and suspended in 150 Al of buffer A [10 mM Tris HCl, pH 7.6/1.5 mM MgCl2/10 mM KCl/0.5 mM dithiothreitol/leupeptin (0.5 ,ug/ml)/pepstatin (20 
RESULTS
Immunologic Characterization and Cellular Localization of the Full-Length Mt-PK (72 kDa). To search for the full-length Mt-PK, a number of different antibodies were tested. It has been reported that antibodies against bacterial fusion protein 10033 and anti-peptide antibody 254 recognized a 55-kDa protein in human skeletal muscle biopsies (5). In addition, antibodies to the peptide Pro-Gly-Thr-Gly-Ser-Tyr-Gly-ProGlu-Cys-Asp-Trp from the Mt-PK kinase domain were developed (antibody 8391). All antibodies recognized the full-length recombinant Mt-PK expressed in pRSET expression vector in bacterial cells (Fig. 1) . In these studies, Mt-PK was purified as a fusion protein from Escherichia coli cells transfected with pRMK, which contains the full-length Mt-PK cDNA coding region in the pRSET expression vector. The molecular size of the Mt-PK fusion protein from pRMK is -75 kDa, which corresponds to the full-length Mt-PK (72 kDa) plus the fusion portion (3 kDa) (Fig. 1A, lane 1) reacts with monoclonal antibodies to the gene 10 leader peptide (Fig. 1B, lane 1), antibody 10033 (Fig. 1B, lane 3) , and anti-peptide antibodies 8391 (Fig. 1B, lane 4) and 254 (5) . Since Western blot analysis shows no immunoreactivity in uninduced bacterial extract (Fig. 1B, lane 2) , we conclude that all three antibodies recognize the same fusion protein. We then determined the immunoreactive proteins recognized from human cultured cells. Western blot analysis of protein extracts from human fibroblast cell lines with antibody 10033 detected the major 72-kDa protein and a minor 55-kDa protein (Fig. 2, lane 1) . Antibody 254 recognized only the 55-kDa isoform from the same protein extracts (Fig. 2, lane 2) and antibody 8391 recognized both 72-kDa and 55-kDa proteins in the total protein extracts from human fibroblast cell line (Fig.  2, lane 3) . Our results demonstrated that two independently developed antibodies to Mt-PK (10033 and 8391) interact with a 72-kDa protein, the predicted full length of Mt-PK. Based on this observation, we suggest that the 72-kDa protein is a full-length translational product of Mt-PK mRNA. The lack of antibody 254 recognition of the 72-kDa protein may reflect a protected epitope in the 72-kDa protein or immunocrossreactivity.
The cellular localization (cytoplasmic and/or nuclear) of the putative immunoreactive Mt-PK proteins was determined from fibroblast cell lines. By using antibody 8391, we detected the 72-kDa protein in the cytoplasm and the 55-kDa protein in the nuclear extract (Fig. 3) .
The Full-Length (72 kDa) Mt-PK Phosphorylation and Kinase Activity. The nucleotide sequence of Mt-PK cDNA shows a high identity with Ser/Thr kinases. However, information about Mt-PK activity is very limited (14, 15) . We investigated whether Mt-PK proteins are phosphorylated in vivo. Human fibroblasts cell line were, therefore, grown with [32P]phosphate and labeled proteins were isolated. Mt-PK was immunoprecipitated with antibody 10033 and analyzed by PAGE on 8% gels. Antibody 10033 interacted with both 72-kDa and 55-kDa isoforms (Fig. 4A) , but only the 72-kDa isoform was phosphorylated by [32P]phosphate in vivo (Fig.  4B) .
To demonstrate protein kinase activity of the full-length Mt-PK in vitro, recombinant fusion Mt-PK was purified from bacterial cells transfected with pRMK and analyzed as described above (Fig. 1A, lane 1) . We first attempted to determine whether Mt-PK demonstrates autophosphorylation, a feature of many other kinases. As a control we used a protein fraction that was isolated from uninduced cells by the same procedure as Mt-PK purification (Fig. 1A, lane 2) . As shown in Fig. SA, lane 2 , the recombinant full-length Mt-PK has strong autophosphorylation but the control protein fraction does not (Fig. 5A, lane 1) . The results of the thin layer chromatography of the radioactive residues from the phosphorylated Mt-PK indicated significant radioactivity in the phosphoserine residue position and minor radioactivity in the phosphothreonine position (data not shown). We then tested whether Mt-PK is a member of an established kinase family by using synthetic peptides, including Arg-Arg-Leu-Ile-Glu-AspAla-Glu-Tyr-Ala-Ala-Arg-Gly (a peptide for Tyr kinase), GlyArg-Gly-Leu-Ser-Leu-Ser-Arg (a substrate for cAMPdependent protein kinase), Pro-Leu-Ala-Arg-Thr-Leu-SerVal-Ala-Gly-Leu-Pro-Gly-Lys-Lys (syntide 2, a substrate for Ca2+/calmodulin-dependent kinase II and for Ca2+/ phospholipid-dependent protein kinase), Pro-Leu-Ser-ArgThr-Leu-Ser-Val-Ala-Ala-Lys-Lys (a substrate for protein kinase C), and Leu-Arg-Arg-Ala-Hse-Leu-Gly (a peptide containing homoserine, Hse). The recombinant Mt-PK significantly phosphorylated the peptide Gly-Arg-Gly-Leu- Ser-Leu-Ser-Arg, a substrate for cAMP-dependent kinases (Fig. SB) . This peptide contains a Ser residue in the phosphorylation site. Collectively, these results indicate that Mt-PK is a member of the Ser/Thr kinase family.
Phosphorylation of the ,3 Subunit of DHPR by Mt-PK. The phosphorylation of DHPR by Mt-PK fusion protein was studied in vitro (Fig. 6A) . Biochemically purified DHPR (17) , kindly provided by S. Hamilton, was used in the reaction mixture with Mt-PK fusion protein. DHPR contains an endogenous kinase that phosphorylates the major proteins of DHPR (18) requiring use of a low concentration of DHPR (60 ,g/ml). As shown in Fig. 6A , lane 2, Mt-PK does not change the phosphorylation of the high molecular weight protein (at subunit) but strongly phosphorylates the 56-kDa protein (( subunit) (19) . Confirmation of the 56-kDa protein as the (3 subunit of DHPR (20) was made by two studies. (i) The subunits of DHPR were phosphorylated as described, electrophoresed, and transferred to nitrocellulose. The membrane was then probed with monoclonal antibodies to the 1B subunit of DHPR. Fig. 6A , lanes 2 and 3, shows that the phosphorylated 56-kDa protein reacting with the antibodies has the same mobility as the 13 subunit of DHPR. (ii) These antibodies were used to precipitate the 56-kDa protein from human muscle biopsy material; this protein was then incubated with recombinant Mt-PK. The recombinant Mt-PK strongly phosphorylated the ,B subunit within the immunoprecipitate (Fig. 6A, lane 5) . Lanes (19) . Recombinant Mt-PK also phosphorylates this peptide (Fig. 6B) .
DISCUSSION
Analysis of Mt-PK cDNA (5) shows that the first in-frame AUG codon is in nt 546. If this AUG codon is the authentic site of initiation, the size of the translation product should be -72 kDa. Mt-PK cDNA contains four additional in-frame AUG codons within the translated region in nt 870, 1017, 1704, and 1836. The initiation of translation from these AUG codons would give alternative protein products with approximate molecular sizes of 59, 55, 30, and 28 kDa, respectively. None of the AUG codons possesses a favorable "Kozak" sequence (21, 22) for translational initiation, so leaky initiation of translation could produce alternative isoforms. It is possible that the 72-kDa protein is a full-length version of Mt-PK and that the 52-to 55-kDa proteins are formed because of alternative initiation of translation. We have investigated the kinetics of 35S-labeling of the 72-and 55-kDa proteins in vivo and found that both proteins had identical kinetics of labeling (unpublished data). Translation of Mt-PK mRNA isolated by selective hybridization in a cell-free system and immunoprecipitation of translational products indicated biosynthesis of the major 72-kDa protein and minor 55-kDa protein (unpublished data). Thus, these observations suggest that the 55-kDa protein probably is an alternative translational product or another kinase with significant homology to Mt-PK.
In these studies, we used two antibodies to Mt-PK (antibodies 10033 and 8391) and showed the existence of an immunoreactive polypeptide with a molecular size of 72 kDa corresponding to the predicted size of the full-length Mt Biochemistry: Timchenko et al cause the 72-kDa Mt-PK was phosphorylated in vivo, we stggest that the kinase activity of the full-length Mt-PK is regulated by phosphorylation. No information is available about the substrate(s) molecule for Mt-PK. Since DM is a muscle disease with defects in muscle excitability, ion channels that are involved in the regulation of muscle activity would be good candidates for biological substrates for Mt-PK. Several disorders are characterized by abnormal muscle membrane hyperexcitability. For most of these diseases, specific mutations have been found in ion channel genes. In Thompsen disease (23) and recessive generalized myotonia (24) , point mutations in chloride channel genes have been found. Point mutations were observed in sodium channel genes in paramyotonia congenita and hyperkalemic periodic paralysis (25) (26) (27) . In hypokalemic periodic paralysis, mutations in the al subunit of DHPR were demonstrated (28) . In this paper we describe the phosphorylation of the Ca2+ channel, ,B subunit of DHPR, by recombinant Mt-PK in vitro as a possible candidate substrate of Mt-PK. The biological role of this phosphorylation should be investigated in vivo, as should the phosphorylation of other ion channels.
